| Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised … E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ... The lancet oncology 18 (9), 1274-1284, 2017 | 1652 | 2017 |
| Olaparib plus bevacizumab as first-line maintenance in ovarian cancer I Ray-Coquard, P Pautier, S Pignata, D Pérol, A González-Martín, ... New England Journal of Medicine 381 (25), 2416-2428, 2019 | 1512 | 2019 |
| Malignant effusions and immunogenic tumour-derived exosomes F Andre, NEC Schartz, M Movassagh, C Flament, P Pautier, P Morice, ... The Lancet 360 (9329), 295-305, 2002 | 1142 | 2002 |
| ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease N Colombo, C Sessa, A Du Bois, J Ledermann, WG McCluggage, ... Annals of Oncology 30 (5), 672-705, 2019 | 1043 | 2019 |
| Cutaneous side-effects of kinase inhibitors and blocking antibodies C Robert, JC Soria, A Spatz, A Le Cesne, D Malka, P Pautier, J Wechsler, ... The lancet oncology 6 (7), 491-500, 2005 | 675 | 2005 |
| Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications P Morice, F Joulie, S Camatte, D Atallah, R Rouzier, P Pautier, C Pomel, ... Journal of the American College of Surgeons 197 (2), 198-205, 2003 | 341 | 2003 |
| Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors P Morice, S Camatte, J El Hassan, P Pautier, P Duvillard, D Castaigne Fertility and sterility 75 (1), 92-96, 2001 | 329 | 2001 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double … A Poveda, A Floquet, JA Ledermann, R Asher, RT Penson, AM Oza, ... The Lancet Oncology 22 (5), 620-631, 2021 | 280 | 2021 |
| Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up I Ray-Coquard, P Morice, D Lorusso, J Prat, A Oaknin, P Pautier, ... Annals of Oncology 29, iv1-iv18, 2018 | 280 | 2018 |
| Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma P Pautier, C Genestie, A Rey, P Morice, B Roche, C Lhommé, ... Cancer 88 (6), 1425-1431, 2000 | 267 | 2000 |
| Detection of minimal levels of serum anti-Mullerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked … WQ Long, V Ranchin, P Pautier, C Belville, P Denizot, H Cailla, ... The Journal of Clinical Endocrinology & Metabolism 85 (2), 540-544, 2000 | 237 | 2000 |
| Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before … S Gouy, P Morice, F Narducci, C Uzan, A Martinez, A Rey, E Bentivegna, ... Lymphadénectomie lombo-aortique extrapéritonéale et single-port dans les …, 2013 | 224 | 2013 |
| Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation … P Pautier, A Floquet, N Penel, S Piperno-Neumann, N Isambert, A Rey, ... The oncologist 17 (9), 1213-1220, 2012 | 221 | 2012 |
| Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study N Delanoy, JM Michot, T Comont, N Kramkimel, J Lazarovici, R Dupont, ... The Lancet Haematology 6 (1), e48-e57, 2019 | 217 | 2019 |
| Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature E Bentivegna, A Maulard, P Pautier, C Chargari, S Gouy, P Morice Fertility and sterility 106 (5), 1195-1211. e5, 2016 | 206 | 2016 |
| Interest of pelvic and paraaortic lymphadenectomy in patients with stage IB and II cervical carcinoma P Morice, D Castaigne, P Pautier, A Rey, C Haie-Meder, M Leblanc, ... Gynecologic oncology 73 (1), 106-110, 1999 | 201 | 1999 |
| Impact of surgical staging in patients with macroscopic “stage I” ovarian borderline tumours: analysis of a continuous series of 101 cases S Camatte, P Morice, A Thoury, V Fourchotte, P Pautier, C Lhomme, ... European Journal of Cancer 40 (12), 1842-1849, 2004 | 193 | 2004 |
| Prognostic factors for patients with advanced stage serous borderline tumours of the ovary P Morice, S Camatte, A Rey, D Atallah, C Lhomme, P Pautier, C Pomel, ... Annals of oncology 14 (4), 592-598, 2003 | 189 | 2003 |
| Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC) SJL Mesnage, A Auguste, C Genestie, A Dunant, E Pain, F Drusch, ... Annals of oncology 28 (3), 651-657, 2017 | 173 | 2017 |
| Cyclophosphamide induces differentiation of Th17 cells in cancer patients S Viaud, C Flament, M Zoubir, P Pautier, A LeCesne, V Ribrag, JC Soria, ... Cancer research 71 (3), 661-665, 2011 | 172 | 2011 |
